JPY 2,076.00
-34.50 (-1.63%)
JPY · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 7733.T is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 with posted results
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe EmphysemaNCT02470052responder rate after deployment of valvesOpen-label · Treatment | Not applicable | Terminated | Device: OL-BF-001 | Emphysema | 38 | Apr 2018actual | 2019-08-28 |
| Spectroscopy From DuodenumNCT01753479The spectral data of the normal cohort and UICC stage II pancreatic ductal adenocarcinoma cohortOpen-label · Diagnostic | Not applicable | Completed | Other: Spectroscopy device | Pancreatic Adenocarcinoma | 445 | 2016-06-30actual | 2017-03-07 |
| Pancreatic Juice Diagnosis From DuodenumNCT01699698results2015-09-03The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma CohortNon-randomized · Single-masked · Diagnostic | Not applicable | Completed | Other: Tumor markers | Pancreatic Adenocarcinoma | 105 | Jul 2014actual | 2015-09-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19